Premium
Validation of a multivariable prediction model for post‐engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Author(s) -
RodríguezVeiga Rebeca,
Montesinos Pau,
García Estefanía,
Boluda Blanca,
Rojas Rafael,
Serrano Josefina,
MartínezCuadrón David,
Martín Carmen,
Sanz Jaime,
Tabares Salvador,
Piñana José L.,
Lorenzo Ignacio,
Montoro Juan,
Salavert Miguel,
Pemán Javier,
Jarque Isidro,
Solves Pilar,
Sanz Guillermo F.,
Torres Antonio,
Sanz Miguel A.
Publication year - 2019
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12891
Subject(s) - cohort , medicine , cumulative incidence , hematopoietic stem cell transplantation , incidence (geometry) , transplantation , voriconazole , surgery , physics , optics , antifungal , dermatology
Summary Background Recently, we reported a simple prognostic score for post‐engraftment invasive fungal disease ( IFD ) obtained in 404 adult allogeneic hematopoietic stem cell transplant (allo SCT ) (training cohort). Objectives We aim to validate this score in an external cohort assessing the 1‐year cumulative incidence ( CI ) of post‐engraftment IFD . Additionally, we analyse the type of IFD and incidence of IFD according to type of prophylaxis. Patients/methods We included 465 consecutive adult recipients surviving >40 days who engrafted and were discharged without prior IFD (median age 45 years, range, 14‐69). Results Patients classified as low‐risk, 139; intermediate‐risk, 162; and high‐risk, 164 (35% vs 27% in the training cohort, P = 0.03). The CI of probable/proven IFD in the validation cohort was 8% vs 11% in the training cohort ( P = 0.006). The only voriconazole prophylaxis used in the training cohort was 100 mg/12 h, 65% vs 27% in the validation cohort, but 38% received 200 mg/12 h. Thus, the validation cohort showed a lower CI of IFD ( P = 0.009). The post‐engraftment IFD score was validated, showing a CI of IFD for low‐, intermediate‐ and high‐risk of 3%, 6% and 14%, respectively ( P < 0.001). Conclusion To our knowledge, this is the first prognostic index to predict the occurrence of post‐engraftment IFD after alloSCT that has been validated in an external cohort.